PackGene Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PackGene Biotech is a leading CRO and CDMO focused on accelerating cell and gene therapy development. The company leverages proprietary technology platforms, such as its π-Alpha 293 system for high-yield AAV production, to serve over 1,000 clients and deliver more than 50,000 projects. With a 120,000 sq. ft. GMP facility and strong endorsements from notable biopharma companies, PackGene is positioned as a critical enabler in the rapidly growing advanced therapies market. Its business model is entirely service-based, providing essential R&D and manufacturing support without an internal therapeutic pipeline.

Gene TherapyCell Therapy

Technology Platform

Proprietary platforms for viral vector and nucleic acid production: π-Alpha 293 (high-yield AAV production), π-Omega (high-yield plasmid DNA production), and π-Icosa (AI-enhanced AAV capsid engineering).

Opportunities

The company is positioned to capitalize on the massive growth and chronic manufacturing bottlenecks in the cell and gene therapy sector.

Its proprietary yield-enhancement technologies directly address the industry's high cost-of-goods challenge, creating a strong value proposition.

Expansion of its AI-driven capsid engineering services could open new revenue streams in vector design.

Risk Factors

Key risks include dependence on the volatile biotech funding environment, intense competition from larger CDMOs, and significant operational/regulatory risks associated with complex viral vector GMP manufacturing.

Technological shifts away from AAV or viral delivery could also impact long-term demand.

Competitive Landscape

PackGene competes in a crowded and growing CDMO space for advanced therapies. It faces competition from large, diversified CDMOs (e.g., Lonza, Catalent) and specialized viral vector players. Its differentiation is based on proprietary yield-enhancing technology, speed, cost-effectiveness, and strong client testimonials from leading biopharma companies.

More companies in Cell & Gene Therapy →More companies in United States →